Skip to content

Your donation DOUBLED through April 30 thanks to anonymous donors who pledged to match your gift!   DONATE NOW!

SCA10

A collection of resources for individuals and families affected by Spinocerebellar Ataxia type 10 (SCA10).

Spinocerebellar Ataxia type 10 (SCA10) is caused by a genetic mutation that is passed on from parents to their children. For complete information about symptoms, diagnosis, and treatment of Ataxia, visit our What is Ataxia? page. This page contains NAF’s resources that are specific to SCA10. 

Sign up for our mailing list to stay up-to-date on Ataxia news.

Webinars

Clinical Care for SCA10

Presented by Mario Cornejo-Olivas, MD

This webinar covers the causes and symptoms of SCA10, the typical diagnostic journey for those affected, and what to expect for clinical care.

Research and Treatment Development for SCA10

Presented by Birgitt Schüle, MD

This webinar covers how SCA10 is studied and gives an overview of the current state of research and drug development for the disease.

NAF offers webinars on many topics to help you live better with Ataxia. Visit www.ataxia.org/webinars to find other helpful presentations.

Research Pipeline

This is a visual tool created to show the progress of all SCA10 therapies that are currently being developed. Along the vertical axis, treatments are grouped by their mechanism, or how the drug works. The horizontal axis shows the stage of research where the drug is in development. Phases 1 through 3 involve clinical trials with human participants. Visit the SCA10 Pipeline page for more details.

Participate in Research and Treatment Development

Participating in a research study or clinical trial is one way to take an active role in furthering understanding and treatment of Ataxia. It is also a way to get access to new treatment options before they are widely available. To find studies that are enrolling patients, visit our Help Develop New Treatments page.

SCA10 Information

Spinocerebellar Ataxia type 10 (SCA10) is one specific type of Ataxia among a group of inherited diseases of the central nervous system. As in other inherited Ataxias, SCA10 is caused by genetic defects that lead to impairment of specific nerve fibers carrying messages to and from the brain, resulting in degeneration of the cerebellum (the coordination center of the brain).

The exact prevalence of SCA10 is not known. SCA10 has been identified only in families of Mexican, Brazilian and several other Latin American heritages. Whenever traceable, the affected ancestor has been of a Native American origin.

SCA10 Symptoms

Typically, problems with balance and coordination (ataxia) are noticed first. (In fact, “ataxia” means incoordination.) The affected person has trouble walking and this difficulty gradually worsens. Falls occur with increasing frequency. As time goes on, the use of a cane, walker, and eventually, a wheelchair will become necessary. Within a few years of onset, slurred speech (dysarthria) is typical due to inability to coordinated movements of the lips, cheeks, tongue, vocal cords, diaphragm, etc. Also, within a few years of onset, coordination of hands and arms becomes impaired. Fine motor skills such as handwriting and fastening buttons are affected first; eventually basic daily tasks such as feeding and dressing become difficult. Abnormal tracking movements of the eyes are common. In the later stages of the disease, difficulty swallowing (dysphasia) results from inability to control muscles in the mouth and throat and aspiration pneumonia may become a life-threating issue.

Recurrent seizures affect 20 percent to 100 percent of those afflicted with SCA10. The seizures are usually seen after the ataxia symptoms first appear. Most commonly recognized are generalized motor seizures, but complex partial seizures also have been seen.

Some individuals with SCA10 have additional symptoms such a mood disorders; weakness or loss of feeling in the feet, legs, or hands (peripheral neuropathy); cognitive dysfunction; and mild pyramidal signs such as overly active reflexes (hyperreflexia) and/or Babinski sign (when the sole of the foot is tickled, the big toe reflex turns up instead of down).

SCA10 Prognosis

Age of affected persons at onset of SCA10 symptoms ranges from 10 to 50 years. SCA10 is a slowly progressive disease, which means symptoms develop gradually over many years. Life span may be shortened by the progressive nature of the disease. Severe seizures may become fatal if not adequately controlled.

SCA10 Genetics

SCA10 is a genetic disorder which means that it is an inherited disease. The abnormal gene responsible for this disease is passed along from generation to generation by family members who carry it. Genetic diseases occur when on the body’s 30,000 genes does not work properly. (Genes are microscopic structures within the cells of our bodies that contain instructions for every feature a person inherits from his or her parents.)

SCA10 is an autosomal dominant disorder. This means that individuals of either sex are equally likely to inherit the gene and develop the disease and the gene passes directly from one generation to the next without skipping generations. Each child of a person with SCA10 had a 50 percent chance of inheriting the gene that causes it.

SCA10 Diagnosis

A neurologist often is the most helpful specialist in recognizing symptoms and diagnosing the diseases that cause Ataxia. Initially, a neurologic examination can determine whether a person has symptoms typical of one of the SCAs. DNA-based testing can accurately detect the presence or absence of the abnormal gene that causes SCA10.

DNA tests for SCA10 involve analysis of a gene located on chromosome 22q13. (Each person has 23 pairs of chromosomes.) Genes are made up of substances known as nucleotides linked together in chains. Each nucleotide is identified by a letter. In SCA10, a gene mutation in a gene called ATXN10, which is located on the 22nd chromosome, results in extra copies of a series of five nucleotides (pentanucleotide) identified by the letters ATTCT.

SCA10 Research News

SCAsource provides Ataxia research news, directly from researchers to the Ataxia community. Visit SCAsource to see their full collection. Here is a collection of articles about SCA10. 

Snapshot: What is Riluzole?

Riluzole, often sold under the trade name Rilutek, is a medication used for the treatment of amyotrophic lateral sclerosis (ALS). ALS is a fatal neurodegenerative disease that mainly affects neurons Read More…

Print Friendly, PDF & Email
Translate »

Join the Ataxia community today!

Become a free member for exclusive content from NAF.